Babcock & Wilcox Enterprises, Inc. current report, 06 June 2018

Business Context and Reporting Period

This Form 8-K Current Report was filed by Babcock & Wilcox Enterprises, Inc. on June 6, 2018, covering events occurring on June 5, 2018. The filing primarily addresses a material impairment and the sale of specific business units.

Key Financial Metrics and Transaction Details

  • Transaction Value: The Company entered into an agreement to sell its MEGTEC and Universal businesses to Dürr AG and Durr Inc. for $130 million, subject to adjustment.
  • Impairment Charge: The Company expects to record a non-cash impairment charge of approximately $80 million to $90 million to revalue assets to fair value less estimated sale costs.
  • Liquidity Impact: Proceeds from the sale are intended to reduce outstanding balances under the Company's bank credit facilities, thereby improving the balance sheet and financial flexibility.
  • Accounting Classification: The MEGTEC and Universal businesses are expected to be classified as "held for sale" under U.S. GAAP.

Material Changes and Outlook

The primary material change is the divestiture of the MEGTEC and Universal businesses. The transaction is expected to close in the third quarter of 2018, subject to customary closing conditions, including approvals from antitrust agencies and the Committee on Foreign Investment in the United States (CFIUS).

Management commentary highlights the strategic intent to enhance liquidity and financial flexibility. However, the filing includes extensive forward-looking statements cautioning that actual results may vary due to risks such as the ability to successfully complete the sale, the final amount of the impairment charge, and the Company's ability to continue as a going concern.

Investor Verification Checklist

  • Verify the final closing date of the MEGTEC and Universal business sale, currently targeted for Q3 2018.
  • Confirm the final approved impairment charge amount, currently estimated between $80 million and $90 million.
  • Monitor regulatory approvals from antitrust agencies and CFIUS required for the transaction to close.
  • Assess the Company's ongoing liquidity position and ability to meet financing obligations post-transaction.
  • Review subsequent filings for updates on the "held for sale" classification and any changes to the estimated sale costs.